Loading clinical trials...
Loading clinical trials...
A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMID, and CD38 Monoclonal Antibody Treatment
Conditions
Interventions
No intervention
Locations
75
United States
Oncology Institute of Hope and Innovation
Glendale, California, United States
Marin Cancer Center
Greenbrae, California, United States
Asclepes Research
Weeki Wachee, Florida, United States
Oncology Hematology Assoc of Central Illinois, P.C. d.b.a. Illinois CancerCare, P.C.
Peoria, Illinois, United States
Providence Cancer Center
Southfield, Michigan, United States
Central Care Cancer Center
Bolivar, Missouri, United States
Start Date
August 2, 2019
Primary Completion Date
October 27, 2022
Completion Date
October 27, 2022
Last Updated
March 30, 2025
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT06138275
NCT05862012
Lead Sponsor
Janssen-Cilag Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions